At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38 enrolled
Drug / intervention
SBRT for Benign Extradural Spine Tumors +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors
In Brief
A clinical study evaluating SBRT for Benign Extradural Spine Tumors and SBRT for Vertebral/Paraspinal Metastases for Spinal Metastases and 8 related conditions. Completed, enrolled 38 participants across 1 site.
Detailed Summary
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedMay 2011
Primary CompletionSep 2017
TodayJul 2026
First PostedMay 4, 2011
Enrollment StartSep 1, 2008
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 15.2 years ago
Interventions
SBRT for Benign Extradural Spine Tumorsradiation
14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
SBRT for Vertebral/Paraspinal Metastasesradiation
12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)